Presentation at The Eight Annual Swedish-American Life Science Summit
8/23/2012 3:30 AM EST
DiaGenic ASA is invited to present at The Eight Annual Swedish-American Life Science Summit August 23rd-24thtogether with lead US, Asian and Nordic life science investors. The company will be presented by interim CEO Henrik Lund in Stockholm on August 23rd.
The presentation material will be available at www.newsweb.no and www.diagenic.com
Contact:
Henrik Lund, CEO
Telephone: 47 90971219
e-mail:
About DiaGenic ASA
DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.
DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).
DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com